mRNA CMC for IND

6-Month IND Solution from plasmid to mRNA

>10 Global IND Approvals

mRNA is known to the public due to the COVID-19 pandemic. The mRNA vaccine made from it has the characteristics of fast response to pathogen variation, simple production process, and large-scale expansion. With the increasing demand for mRNA vaccines, the industry has also begun to realize the feasibility and advantages of mRNA vaccines/drugs, followed by an increasing number of clinical applications for mRNA vaccines.

ProBio provides one-stop solution from plasmid and linearized DNA manufacturing, IVT-mRNA preparation, LNP encapsulation, sterile filtration and IND filing. Combined with the experience of multiple previous projects, it helps customers' projects to accelerate into the clinical trial stage.